Elicera Therapeutics postpones final reporting of ELC-100 study due to database transition

Gothenburg, June 11, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces today that the final reporting from the dose-escalation study with the drug candidate ELC-100 has been delayed. The plan was to report data during the summer, but based on new information from the contract research organization (CRO) responsible for the study's database and analysis, the study results are now expected to be reported before the end of 2025.

Elicera Therapeutics is developing ELC-100 as a potential treatment for neuroendocrine tumors (NET). The drug candidate, based on an oncolytic virus, exerts its therapeutic effect by selectively infecting and killing neuroendocrine cancer cells. The Phase I/IIa clinical trial aims to identify the maximum tolerated dose (MTD) and assess the treatment’s safety in patients.

Based on new information from the contract research organization (CRO) responsible for compiling the study database and collecting and analyzing data, the database cannot be closed before the summer as previously planned. The delay is partly due to the study, which has been ongoing since 2016, having to switch to a new database solution after the original database was discontinued. This has required additional time to migrate and validate data to a new platform. The CRO now estimates that the database can be closed by the fall, with final reporting expected before the end of 2025.

"We recognize that the unexpected delay of the study report until the fourth quarter of 2025 may cause frustration among our shareholders and stakeholders, and we share this sentiment. The technical transition to a new database platform has proven more complex than anticipated, which we could not foresee in our original planning. Our priority is to ensure robust and reliable study results, and we are working intensively to complete the process as quickly as possible, with the goal of delivering high-quality data by Q4 2025 at the latest," says Jamal El-Mosleh, CEO of Elicera Therapeutics.

About ELC-100

Elicera’s oncolytic virus therapy ELC-100 is a genetically modified virus capable of selectively infecting, replicating in, and killing neuroendocrine cancer cells without harming healthy cells. The company’s ongoing dose-escalation clinical trial (Phase I/IIa) is fully funded by the VictoryNET-Foundation and is expected to report final data by mid-2025.

About Elicera Therapeutics AB
Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.

For further information, please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)

Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com

Certified Advisor

Mangold Fondkommission AB